Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Baxter
Moodys
Express Scripts
Mallinckrodt

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Doxorubicin Hydrochloride (liposomal)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001059 ↗ Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS Completed Amgen Phase 2 1969-12-31 To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00001059 ↗ Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS Completed Sequus Pharmaceuticals Phase 2 1969-12-31 To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00001059 ↗ Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00002093 ↗ A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed Nexstar Pharmaceuticals Phase 3 1969-12-31 To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy. To compare the duration of responses, response rates, and times to response.
NCT00002105 ↗ Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed Sequus Pharmaceuticals Phase 3 1969-12-31 To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a population of AIDS patients with moderate to severe KS.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Doxorubicin Hydrochloride (liposomal)

Condition Name

Condition Name for Doxorubicin Hydrochloride (liposomal)
Intervention Trials
Ovarian Cancer 67
Breast Cancer 55
Fallopian Tube Cancer 29
Multiple Myeloma 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Doxorubicin Hydrochloride (liposomal)
Intervention Trials
Ovarian Neoplasms 124
Carcinoma, Ovarian Epithelial 99
Breast Neoplasms 79
Fallopian Tube Neoplasms 55
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Doxorubicin Hydrochloride (liposomal)

Trials by Country

Trials by Country for Doxorubicin Hydrochloride (liposomal)
Location Trials
Italy 135
China 68
Spain 63
Germany 57
Canada 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Doxorubicin Hydrochloride (liposomal)
Location Trials
California 78
New York 66
Texas 58
Florida 50
Ohio 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Doxorubicin Hydrochloride (liposomal)

Clinical Trial Phase

Clinical Trial Phase for Doxorubicin Hydrochloride (liposomal)
Clinical Trial Phase Trials
Phase 4 10
Phase 3 63
Phase 2/Phase 3 8
[disabled in preview] 209
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Doxorubicin Hydrochloride (liposomal)
Clinical Trial Phase Trials
Completed 170
Terminated 52
Unknown status 46
[disabled in preview] 69
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Doxorubicin Hydrochloride (liposomal)

Sponsor Name

Sponsor Name for Doxorubicin Hydrochloride (liposomal)
Sponsor Trials
National Cancer Institute (NCI) 65
Merck Sharp & Dohme Corp. 12
M.D. Anderson Cancer Center 12
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Doxorubicin Hydrochloride (liposomal)
Sponsor Trials
Other 390
Industry 241
NIH 68
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Johnson and Johnson
Harvard Business School
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.